Circulating microRNAs as biomarkers in progressive multiple sclerosis

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Multiple Sclerosis

• Publication date

  2017-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/1352458516651141PMID 27246141
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Efficacy and safety of ocrelizumab in relapsing multiple sclerosis: Results of the IFN-β-1a-controlled, double-blind, Phase III OPERA I and II studies

  2016cited by this paper
• Analysis of genes, pathways and networks involved in disease severity and age at onset in primary-progressive multiple sclerosis

  2015cited by this paper
• Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study

  2015cited by this paper
• miRNA in multiple sclerosis: search for novel biomarkers

  2015cited by this paper
• Role of the innate and adaptive immune responses in the course of multiple sclerosis.

  2015cited by this paper
• MicroRNA-155 modulates Th1 and Th17 cell differentiation and is associated with multiple sclerosis and experimental autoimmune encephalomyelitis.

  2014cited by this paper
• A reciprocal antagonism between miR‐376c and TGF‐β signaling regulates neural differentiation of human pluripotent stem cells

  2014cited by this paper
• Brain microRNAs and insights into biological functions and therapeutic potential of brain enriched miRNA-128

  2014cited by this paper
• Selected Extracellular microRNA as Potential Biomarkers of Multiple Sclerosis Activity—Preliminary Study

  2014cited by this paper
• Downregulation of microRNA-24 and -181 parallels the upregulation of IFN-γ secreted by activated human CD4 lymphocytes.

  2014cited by this paper
• miR-191: an emerging player in disease biology

  2014cited by this paper
• Natalizumab in progressive MS

  2014cited by this paper
• The dual role of transforming growth factor beta in the pathogenesis of multiple sclerosis and experimental autoimmune encephalomyelitis

  2014cited by this paper
• MicroRNA-376c Impairs Transforming Growth Factor-&bgr; and Nodal Signaling to Promote Trophoblast Cell Proliferation and Invasion

  2013cited by this paper
• Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis

  2013cited by this paper
• Circulating miRNA Biomarkers for Alzheimer's Disease

  2013cited by this paper
• Systemic Inflammation in Progressive Multiple Sclerosis Involves Follicular T-Helper, Th17- and Activated B-Cells and Correlates with Progression

  2013cited by this paper
• Comprehensive Expression Analyses of Neural Cell-Type-Specific miRNAs Identify New Determinants of the Specification and Maintenance of Neuronal Phenotypes

  2013cited by this paper
• Trash or Treasure: extracellular microRNAs and cell-to-cell communication

  2013cited by this paper
• miR128 up-regulation correlates with impaired amyloid β(1-42) degradation in monocytes from patients with sporadic Alzheimer's disease.

  2013cited by this paper
• Differential microRNA expression in blood in multiple sclerosis

  2013cited by this paper
• Circulating MicroRNAs as biomarkers for disease staging in multiple sclerosis

  2013cited by this paper
• DIANA miRPath v.2.0: investigating the combinatorial effect of microRNAs in pathways

  2012cited by this paper
• Plasma ubiquitin–proteasome system profile in patients with multiple sclerosis: correlation with clinical features, neuroimaging, and treatment with interferon-beta-1b

  2012cited by this paper
• Altered microRNA expression in B lymphocytes in multiple sclerosis: towards a better understanding of treatment effects.

  2012cited by this paper
• Circulating microRNAs involved in multiple sclerosis

  2012cited by this paper
• Micro-RNA dysregulation in multiple sclerosis favours pro-inflammatory T-cell-mediated autoimmunity.

  2011cited by this paper
• TGF-β signaling is altered in the peripheral blood of subjects with multiple sclerosis.

  2011cited by this paper
• A novel mean-centering method for normalizing microRNA expression from high-throughput RT-qPCR data

  2011cited by this paper
• Gene silencing by microRNAs: contributions of translational repression and mRNA decay

  2011cited by this paper
• Mitochondria, calcium and cell death: a deadly triad in neurodegeneration.

  2009cited by this paper
• MicroRNA in autoimmunity and autoimmune diseases.

  2009cited by this paper
• Heterogeneous dysregulation of microRNAs across the autism spectrum

  2008cited by this paper
• A miRNA Signature of Prion Induced Neurodegeneration

  2008cited by this paper
• The EGF receptor family: spearheading a merger of signaling and therapeutics.

  2007cited by this paper
• Regulation of miRNA expression during neural cell specification

  2005cited by this paper
• Oligodendrocyte injury in multiple sclerosis: a role for p53

  2003cited by this paper
• Recommended diagnostic criteria for multiple sclerosis: Guidelines from the international panel on the diagnosis of multiple sclerosis

  2001cited by this paper
• On the evaluation of disability in multiple sclerosis

  1998cited by this paper

• Extracellular vesicle-derived miR-760 as a novel promising candidate biomarker differentiating stable RRMS from SPMS

  2026influential citation
• Decoding the Potential Impact of Plasma hsa-miR-24-3p and hsa-miR-181 d-3p Expression, Plasma IFN-γ Levels, and IFNG rs2069727 T/C Genetic Variant on Multiple Sclerosis Risk and Glatiramer Acetate Treatment

  2025influential citation
• Genomic ncRNAs regulating mitochondrial function in neurodegeneration: a neglected clue in the complex etiopathogenesis of multiple sclerosis

  2025cites this paper
• Advancing Ischemic Stroke Prognosis: Key Role of MiR-155 Non-Coding RNA

  2025cites this paper
• Enhanced expression of miR-128 in peripheral blood mononuclear cells: a potent candidate diagnostic biomarker for multiple sclerosis

  2025cites this paper
• Exosomal microRNAs as Early Transition Biomarkers from Recurrent-Remissive to Secondary Progressive Multiple Sclerosis

  2025cites this paper
• From Molecules to Models: miRNAs and Advanced Human Platforms of Neurodegeneration and Repair in Multiple Sclerosis

  2025cites this paper
• Association of MicroRNA Expression and Serum Neurofilament Light Chain Levels with Clinical and Radiological Findings in Multiple Sclerosis

  2024cites this paper
• Serum miR-34a-5p, miR-103a-3p, and miR-376a-3p as possible biomarkers of conversion from relapsing-remitting to secondary progressive multiple sclerosis.

  2024cites this paper
• Exploring the versatility of miRNA-128: a comprehensive review on its role as a biomarker and therapeutic target in clinical pathways

  2024cites this paper
• Potential biomarkers for multiple sclerosis stage from targeted proteomics and microRNA sequencing

  2024cites this paper
• Possible Roles of Extracellular Vesicles in the Pathogenesis and Interventions of Immune-Mediated Central Demyelinating Diseases

  2024cites this paper
• MicroRNA frontiers: Illuminating early detection paths in multiple sclerosis.

  2024cites this paper
• The role of microRNAs involved in the disorder of blood–brain barrier in the pathogenesis of multiple sclerosis

  2023cites this paper
• Insight into Early Diagnosis of Multiple Sclerosis by Targeting Prognostic Biomarkers.

  2023cites this paper
• Multimodal diagnostics in multiple sclerosis: predicting disability and conversion from relapsing-remitting to secondary progressive disease course – protocol for systematic review and meta-analysis

  2023cites this paper
• The role of miRNAs in multiple sclerosis pathogenesis, diagnosis, and therapeutic resistance.

  2023cites this paper
• Circulating microRNAs correlate with structural and functional MRI parameters in patients with multiple sclerosis

  2023cites this paper
• Exploring the impact of miR-128 in inflammatory diseases: A comprehensive study on autoimmune diseases.

  2023cites this paper
• Non-coding RNAs in disease: from mechanisms to therapeutics

  2023cites this paper
• Implication of genetic variants in primary microRNA processing sites in the risk of multiple sclerosis

  2022cites this paper
• miR-150-5p and let-7b-5p in Blood Myeloid Extracellular Vesicles Track Cognitive Symptoms in Patients with Multiple Sclerosis

  2022cites this paper
• miRNAs in multiple sclerosis: A clinical approach.

  2022cites this paper
• Mesenchymal Stem Cell-Derived Extracellular Vesicles and Their Therapeutic Use in Central Nervous System Demyelinating Disorders

  2022cites this paper
• An Update on Diagnostic Laboratory Biomarkers for Multiple Sclerosis

  2022cites this paper
• Versatile role of miR-24/24-1*/24-2* expression in cancer and other human diseases.

  2022cites this paper
• piRNA and miRNA Can Suppress the Expression of Multiple Sclerosis Candidate Genes

  2022cites this paper
• Emerging Biomarkers of Multiple Sclerosis in the Blood and the CSF: A Focus on Neurofilaments and Therapeutic Considerations

  2022cites this paper
• MicroRNAs 181a and 125a are highly expressed in early diagnosed RRMS: a pilot case-control study

  2022cites this paper
• Temporal variability of serum miR-191, miR-223, miR-128, and miR-24 in multiple sclerosis: A 4-year follow-up study.

  2022cites this paper
• Integrated Analysis and Identification of CSF-Derived Risk miRNAs and Pivotal Genes in Multiple Sclerosis

  2022cites this paper
• Association between miRNAs expression and multiple sclerosis pathogenesis: A novel therapeutic approach

  2021cites this paper
• Trends in Biomarkers of Neurodegenerative Diseases

  2021cites this paper
• Non-coding RNAs in the Pathogenesis of Multiple Sclerosis

  2021cites this paper
• Extracellular Vesicles, Stem Cells and the Role of miRNAs in Neurodegeneration

  2021cites this paper
• Role of MicroRNAs, Aptamers in Neuroinflammation and Neurodegenerative Disorders

  2021cites this paper
• Serum Based miRNA as a Diagnostic Biomarker for Multiple Sclerosis: a Systematic Review and Meta-Analysis

  2021cites this paper
• Imprinted Genes and Multiple Sclerosis: What Do We Know?

  2021cites this paper
• Circulating miRNAs as Potential Biomarkers Distinguishing Relapsing–Remitting from Secondary Progressive Multiple Sclerosis. A Review

  2021cites this paper
• A hypothesis-generating scoping review of miRs identified in both multiple sclerosis and dementia, their protein targets, and miR signaling pathways.

  2020cites this paper
• Clinical Application of Circulating MicroRNAs in Parkinson's Disease: The Challenges and Opportunities as Diagnostic Biomarker

  2020cites this paper
• A Meta-Analytic Review of the Value of miRNA for Multiple Sclerosis Diagnosis

  2020cites this paper
• Identification and functional analysis of specific MS risk miRNAs and their target genes.

  2020cites this paper
• Altered Expression of Circulating miR-377 and miR-98 in Relapsing-remitting Multiple Sclerosis

  2020cites this paper
• Upregulated serum miR‐128‐3p in progressive and relapse‐free multiple sclerosis patients

  2020cites this paper
• Epigenetics in Allergy and Autoimmunity

  2020cites this paper
• Epigenetics in Multiple Sclerosis.

  2020cites this paper
• Erythrocyte microRNAs show biomarker potential and implicate multiple sclerosis susceptibility genes

  2020cites this paper
• Early diagnosis of secondary progressive multiple sclerosis: focus on fluid and neurophysiological biomarkers

  2020cites this paper
• The Role of MicroRNAs in Repair Processes in Multiple Sclerosis

  2020cites this paper
• Molecular Biomarkers in Multiple Sclerosis and Its Related Disorders: A Critical Review

  2020cites this paper
• The role of microRNAs in multiple sclerosis

  2020influential citation
• Biomarkers in Rare Demyelinating Disease of the Central Nervous System

  2020cites this paper
• Radiologically isolated syndrome: targeting miRNAs as prognostic biomarkers.

  2020cites this paper
• Immunopathogenesis

  2019cites this paper
• Up-regulation of circulating miR-93-5p in patients with relapsing-remitting multiple sclerosis

  2019cites this paper
• Multiple Sclerosis: Unraveling the Neuropathology and Mechanisms of Neurodegeneration

  2019cites this paper
• Analysis of miRNA signatures in CSF identifies upregulation of miR-21 and miR-146a/b in patients with multiple sclerosis and active lesions

  2019cites this paper
• Serum Exosome MicroRNAs Predict Multiple Sclerosis Disease Activity after Fingolimod Treatment

  2019cites this paper
• MicroRNAs in blood and cerebrospinal fluid as diagnostic biomarkers of multiple sclerosis and to monitor disease progression

  2019influential citation
• Role of Exosomes in Central Nervous System Diseases

  2019cites this paper
• Circulating miR-193b-3p and miR-376a-3p Involved in Iranian Patients with Multiple Sclerosis

  2019cites this paper
• Variability of the MIR 196 A 2 Gene as a Risk Factor in Primary-Progressive Multiple Sclerosis Development

  2019cites this paper
• Variability of the MIR196A2 Gene as a Risk Factor in Primary-Progressive Multiple Sclerosis Development

  2019cites this paper
• Identification of plasma microRNA expression changes in multiple system atrophy and Parkinson’s disease

  2019cites this paper
• Panoramic Visualization of Circulating MicroRNAs Across Neurodegenerative Diseases in Humans

  2019cites this paper
• MiRNAs from DLK1-DIO3 Imprinted Locus at 14q32 are Associated with Multiple Sclerosis: Gender-Specific Expression and Regulation of Receptor Tyrosine Kinases Signaling

  2019cites this paper
• Current and Novel Strategies for Biomarkers Detection in Neurodegenerative Diseases: Future Graphene-Based Applications

  2018cites this paper
• Risk factor effect of rs1044165 and rs3745453 as neighboring variants of miR-223, miR-24, miR-23a and miR-27a on the onset of MS disease in Isfahan/Iran

  2018cites this paper
• Dysregulation of MicroRNAs and Target Genes Networks in Peripheral Blood of Patients With Sporadic Amyotrophic Lateral Sclerosis

  2018cites this paper
• Circulating exosomes suppress the induction of regulatory T cells via let-7i in multiple sclerosis

  2018cites this paper
• MicroRNA Alterations in the Brain and Body Fluids of Humans and Animal Prion Disease Models: Current Status and Perspectives

  2018cites this paper
• Serum and thyroid tissue level of let-7b and their correlation with TRAb in Graves’ disease

  2018cites this paper
• Dysregulated Network of miRNAs Involved in the Pathogenesis of Multiple Sclerosis.

  2018cites this paper
• miRNA-based signatures in cerebrospinal fluid as potential diagnostic tools for early stage Parkinson’s disease

  2018cites this paper
• Combined microRNA and mRNA expression analysis in pediatric multiple sclerosis: an integrated approach to uncover novel pathogenic mechanisms of the disease

  2018cites this paper
• Evaluation of serum miR‐191‐5p, miR‐24‐3p, miR‐128‐3p, and miR‐376c‐3 in multiple sclerosis patients

  2018cites this paper
• Corrigendum: Dysregulation of MicroRNAs and Target Genes Networks in Peripheral Blood of Patients With Sporadic Amyotrophic Lateral Sclerosis

  2018cites this paper
• The miRNA Expression Profile of Experimental Autoimmune Encephalomyelitis Reveals Novel Potential Disease Biomarkers

  2018cites this paper
• Molecular Characterization of Peripheral Extracellular Vesicles in Clinically Isolated Syndrome: Preliminary Suggestions from a Pilot Study

  2017cites this paper
• Biomarkers of multiple sclerosis: current findings

  2017cites this paper
• miR-128 Is Implicated in Stress Responses by Targeting MAFG in Skeletal Muscle Cells

  2017cites this paper
• Composite Marker of Cognitive Dysfunction and Brain Atrophy is Highly Accurate in Discriminating Between Relapsing-Remitting and Secondary Progressive Multiple Sclerosis

  2017cites this paper
• Precision medicine for multiple sclerosis: an update of the available biomarkers and their use in therapeutic decision making

  2017cites this paper
• Recent developments in circulating biomarkers in Parkinson's disease: the potential use of miRNAs in a clinical setting.

  2016cites this paper
• A Personalized Approach in Progressive Multiple Sclerosis: The Current Status of Disease Modifying Therapies (DMTs) and Future Perspectives

  2016cites this paper